Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitric Oxide  COVID-19 treatment studies for Nitric Oxide  C19 studies: Nitric Oxide  Nitric Oxide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro
Akaberi et al., Redox Biology, doi:10.1016/j.redox.2020.101734 (In Vitro)
Akaberi et al., Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro, Redox Biology, doi:10.1016/j.redox.2020.101734 (In Vitro)
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In Vitro study showing that nitric oxide can inhibit the replication of SARS-CoV-2 in Vero E6 cells, and identifying the SARS-CoV-2 main protease as a target for nitric oxide.
Akaberi et al., 31 Oct 2020, Sweden, peer-reviewed, 8 authors.
Contact: ake.lundkvist@imbim.uu.se.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperNitric OxideAll
Abstract: Redox Biology 37 (2020) 101734 Contents lists available at ScienceDirect Redox Biology journal homepage: www.elsevier.com/locate/redox Research Paper Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro Dario Akaberi a, Janina Krambrich a, Jiaxin Ling a, Chen Luni b, Göran Hedenstierna c, Josef D. Järhult d, Johan Lennerstrand e, Åke Lundkvist a, * a Department of Medical Biochemistry and Microbiology, Zoonosis Science Center, Uppsala University, Uppsala, Sweden Department of Microbiology and Tumour and Cell Biology (MTC), Karolinska Institute, Solna, Sweden c Department of Medical Sciences, Section of Clinical Physiology, Uppsala University, Uppsala, Sweden d Department of Medical Sciences, Zoonosis Science Center, Uppsala University, Uppsala, Sweden e Department of Medical Sciences, Section of Clinical Microbiology, Uppsala University, Uppsala, Sweden b A R T I C L E I N F O A B S T R A C T Keywords: SARS-CoV-2 COVID-19 Nitric oxide 3CL protease FRET The ongoing SARS-CoV-2 pandemic is a global public health emergency posing a high burden on nations’ health care systems and economies. Despite the great effort put in the development of vaccines and specific treatments, no prophylaxis or effective therapeutics are currently available. Nitric oxide (NO) is a broad-spectrum antimi­ crobial and a potent vasodilator that has proved to be effective in reducing SARS-CoV replication and hypoxia in patients with severe acute respiratory syndrome. Given the potential of NO as treatment for SARS-CoV-2 infection, we have evaluated the in vitro antiviral effect of NO on SARS-CoV-2 replication. The NO-donor Snitroso-N-acetylpenicillamine (SNAP) had a dose dependent inhibitory effect on SARS-CoV-2 replication, while the non S-nitrosated NAP was not active, as expected. Although the viral replication was not completely abol­ ished (at 200 μM and 400 μM), SNAP delayed or completely prevented the development of viral cytopathic effect in treated cells, and the observed protective effect correlated with the level of inhibition of the viral replication. The capacity of the NO released from SNAP to covalently bind and inhibit SARS-CoV-2 3CL recombinant protease in vitro was also tested. The observed reduction in SARS-CoV-2 protease activity was consistent with S-nitrosation of the enzyme active site cysteine.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit